MedTrace Logo

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

NCT07272109 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-12-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.

Conditions

Interventions

DRUG

Nab-paclitaxel

120 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks

DRUG

Gemcitabine (1000 mg/m2)

(1000 mg per square meter) on days 1, 8, and 15 every 4 weeks

OTHER

Anti-Diabetics

Metformin, insulin or other anti-diabetic treatments

OTHER

Active treatment and monitoring

Attend follow-ups at designated endocrinology clinics, with proactive inquiry about hypoglycemic measures and medication implementation.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Guopei Luo, MD · Shanghai Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272109 on ClinicalTrials.gov